These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 12020953

  • 1. Inhibition of microglial CD40 expression by pituitary adenylate cyclase-activating polypeptide is mediated by interleukin-10.
    Kim WK, Ganea D, Jonakait GM.
    J Neuroimmunol; 2002 May; 126(1-2):16-24. PubMed ID: 12020953
    [Abstract] [Full Text] [Related]

  • 2. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia.
    Delgado M, Leceta J, Ganea D.
    J Leukoc Biol; 2003 Jan; 73(1):155-64. PubMed ID: 12525573
    [Abstract] [Full Text] [Related]

  • 3. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.
    Delgado M, Jonakait GM, Ganea D.
    Glia; 2002 Aug; 39(2):148-61. PubMed ID: 12112366
    [Abstract] [Full Text] [Related]

  • 4. VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression.
    Delgado M, Sun W, Leceta J, Ganea D.
    J Immunol; 1999 Oct 15; 163(8):4213-23. PubMed ID: 10510358
    [Abstract] [Full Text] [Related]

  • 5. VIP and PACAP induce shift to a Th2 response by upregulating B7.2 expression.
    Delgado M, Leceta J, Sun W, Gomariz RP, Ganea D.
    Ann N Y Acad Sci; 2000 Oct 15; 921():68-78. PubMed ID: 11193881
    [Abstract] [Full Text] [Related]

  • 6. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression.
    Delgado M, Leceta J, Gomariz RP, Ganea D.
    J Immunol; 1999 Oct 01; 163(7):3629-35. PubMed ID: 10490956
    [Abstract] [Full Text] [Related]

  • 7. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
    Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D.
    J Immunol; 1999 Feb 01; 162(3):1707-16. PubMed ID: 9973433
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Neurotrophins and the anti-inflammatory agents interleukin-4 (IL-4), IL-10, IL-11 and transforming growth factor-beta1 (TGF-beta1) down-regulate T cell costimulatory molecules B7 and CD40 on cultured rat microglia.
    Wei R, Jonakait GM.
    J Neuroimmunol; 1999 Mar 01; 95(1-2):8-18. PubMed ID: 10229111
    [Abstract] [Full Text] [Related]

  • 10. VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells.
    Delgado M, Reduta A, Sharma V, Ganea D.
    J Leukoc Biol; 2004 Jun 01; 75(6):1122-30. PubMed ID: 15020654
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells.
    Cai Y, Xin X, Shim GJ, Mokuno Y, Uehara H, Yamada T, Agui T, Matsumoto K.
    Endocrinology; 1997 Jun 01; 138(6):2515-20. PubMed ID: 9165043
    [Abstract] [Full Text] [Related]

  • 15. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity.
    Ganea D, Delgado M.
    Crit Rev Oral Biol Med; 2002 Jun 01; 13(3):229-37. PubMed ID: 12090463
    [Abstract] [Full Text] [Related]

  • 16. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells.
    Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D.
    J Neuroimmunol; 1999 May 03; 96(2):167-81. PubMed ID: 10337915
    [Abstract] [Full Text] [Related]

  • 17. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3.
    Delgado M, Ganea D.
    J Immunol; 2001 Jan 15; 166(2):1028-40. PubMed ID: 11145682
    [Abstract] [Full Text] [Related]

  • 18. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by inhibiting Fas ligand expression.
    Delgado M, Ganea D.
    J Immunol; 2000 Feb 01; 164(3):1200-10. PubMed ID: 10640731
    [Abstract] [Full Text] [Related]

  • 19. Pituitary adenylate cyclase-activating polypeptide (PACAP) ameliorates experimental autoimmune encephalomyelitis by suppressing the functions of antigen presenting cells.
    Kato H, Ito A, Kawanokuchi J, Jin S, Mizuno T, Ojika K, Ueda R, Suzumura A.
    Mult Scler; 2004 Dec 01; 10(6):651-9. PubMed ID: 15584490
    [Abstract] [Full Text] [Related]

  • 20. PACAP and VIP Modulate LPS-Induced Microglial Activation and Trigger Distinct Phenotypic Changes in Murine BV2 Microglial Cells.
    Karunia J, Niaz A, Mandwie M, Thomas Broome S, Keay KA, Waschek JA, Al-Badri G, Castorina A.
    Int J Mol Sci; 2021 Oct 11; 22(20):. PubMed ID: 34681607
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.